Comments on Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin-naïve type 2 diabetes patients: cost-effectiveness analysis in the UK setting.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples